AN2 Therapeutics, Inc. (ANTX)

NASDAQ: ANTX · IEX Real-Time Price · USD
10.50
+0.31 (3.04%)
Aug 8, 2022 4:00 PM EDT - Market closed

Company Description

AN2 Therapeutics is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs.

Our initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.

Epetraborole has broad spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. Its novel mechanism of action is enabled by boron chemistry, our core technology approach.

We plan to conduct a Phase 2/3 pivotal clinical trial in treatment-refractory Mycobacterium avium complex, or MAC, lung disease, which is the most common type of NTM lung disease.

We believe our Phase 2/3 pivotal clinical trial design, which is under review by the FDA, has the potential to be sufficient for regulatory approval in the United States.

We recently received clearance of our Investigational New Drug, or IND, application by the FDA to begin our Phase 1 renal impairment study, for which enrollment commenced in February 2022, and plan to initiate patient enrollment in our Phase 2/3 pivotal clinical trial in the first half of 2022.

We also recently received Fast Track designation by the FDA to investigate epetraborole for treatment-refractory MAC lung disease. Epetraborole has also recently been designated as a Qualified Infectious Disease Product, or QIDP, for treatment-refractory MAC lung disease by the FDA and received FDA orphan drug designation for the treatment of infections caused by NTM.

AN2 Therapeutics, Inc.
Country United States
Founded 2017
IPO Date Mar 25, 2022
Industry Biotechnology
Sector Health Care
Employees 22
CEO Eric Easom

Contact Details

Address:
1800 El Camino Real, Suite D
Menlo Park, CA 94027
United States
Phone 650-331-9090
Website an2therapeutics.com

Stock Details

Ticker Symbol ANTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
IPO Price $15.00
CIK Code 1880438
SIC Code 2834

Key Executives

Name Position
Joseph S. Zakrzewski Co-founder and Independent Chairman
Eric E. Easom Co-founder, Chief Executive Officer, President and Director
Lucy O. Day CPA Chief Financial Officer, Secretary and Treasurer
Dr. Paul Eckburg M.D. Chief Medical Officer
Dr. George Harrison Talbot FACP, M.D. Co-Founder and Senior Clinical Advisor
Dr. Michael R. K. Alley Ph.D. Co-Founder and Head of Biology
Dr. Sanjay Chanda Ph.D. Chief Development Officer
Kevin Krause B.S., M.B.A. Chief Strategy Officer
Jennifer Huber Senior Vice President of Regulatory Affairs and Quality
Michael A. Nazak Vice President and Controller

Latest SEC Filings

Date Type Title
Aug 5, 2022 4 Statement of changes in beneficial ownership of securities
Jul 28, 2022 4 Statement of changes in beneficial ownership of securities
Jun 29, 2022 8-K Current report
Jun 24, 2022 4 Statement of changes in beneficial ownership of securities
Jun 24, 2022 4 Statement of changes in beneficial ownership of securities
Jun 24, 2022 4/A Statement of changes in beneficial ownership of securities
Jun 24, 2022 3/A Initial statement of beneficial ownership of securities
Jun 23, 2022 4 Statement of changes in beneficial ownership of securities
Jun 15, 2022 4 Statement of changes in beneficial ownership of securities
May 16, 2022 4 Statement of changes in beneficial ownership of securities